Market Overview

Sterne Agee Initiates Boston Scientific At Neutral

Share:
Related BSX
Analyst: Boston Scientific's Acquisition Is 'Strategically Sound'
Benzinga's M&A Chatter for Monday March 2, 2015
Seeking Alpha's Biotech Weekly: AbbVie - Pharmacyclitics, Orexigen Confusion, And More (Seeking Alpha)

Sterne Agee initiated coverage on shares of Boston Scientific (NYSE: BSX) with a Neutral rating.

The target price for Boston Scientific is set to $13.50.

Boston Scientific shares have surged 19.76% over the past 52 weeks, while the S&P 500 index has gained 17.38% in the same period.

Boston Scientific's shares dropped 1.07% to close at $12.97 yesterday.

Latest Ratings for BSX

DateFirmActionFromTo
Mar 2015OppenheimerMaintainsPerform
Feb 2015Deutsche BankMaintainsHold
Feb 2015JP MorganMaintainsOverweight

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Sterne AgeeInitiation Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...